Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call


Wednesday, 23 Jan 2013 10:00pm EST 

Cubist Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues to be $1.000-$1.045 billion. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.035 billion for fiscal 2013. 

Company Quote

61.66
0.11 +0.18%
30 Jul 2014